drugset / Trial / NCT00053495

Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

NCT00053495

Phase 2 Completed 353 enrolled Emergent BioSolutions
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to examine the safety and the effectiveness of a new vaccine for the prevention of the disease, smallpox.

Timeline

Start
2003-01
Primary completion
2003-06
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ACAM2000 Vaccine 1e-08 unknown
Subject ACAM2000 Vaccine 2e-08 unknown
Subject ACAM2000 Vaccine 1e-07 unknown
Subject ACAM2000 Vaccine 5e-06 unknown
Comparator Dryvax Vaccine 1e-08 unknown

Indications